A detailed history of Jpmorgan Chase & CO transactions in Aura Biosciences, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 53,502 shares of AURA stock, worth $489,008. This represents 0.0% of its overall portfolio holdings.

Number of Shares
53,502
Previous 25,784 107.5%
Holding current value
$489,008
Previous $194,000 145.36%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$6.9 - $10.36 $191,254 - $287,158
27,718 Added 107.5%
53,502 $476,000
Q2 2024

Aug 12, 2024

BUY
$6.81 - $7.89 $10,208 - $11,827
1,499 Added 6.17%
25,784 $194,000
Q1 2024

May 10, 2024

BUY
$7.09 - $9.24 $42,008 - $54,747
5,925 Added 32.27%
24,285 $190,000
Q4 2023

Feb 12, 2024

SELL
$7.02 - $11.98 $1,972 - $3,366
-281 Reduced 1.51%
18,360 $162,000
Q3 2023

Nov 14, 2023

SELL
$8.97 - $12.38 $27,179 - $37,511
-3,030 Reduced 13.98%
18,641 $167,000
Q2 2023

Aug 11, 2023

BUY
$8.51 - $13.33 $27,002 - $42,296
3,173 Added 17.15%
21,671 $267,000
Q1 2023

May 18, 2023

BUY
$8.88 - $12.11 $160,905 - $219,433
18,120 Added 4793.65%
18,498 $171,000
Q1 2023

May 11, 2023

SELL
$8.88 - $12.11 $92,067 - $125,556
-10,368 Reduced 96.48%
378 $3,000
Q4 2022

Feb 13, 2023

BUY
$9.86 - $14.59 $7,227 - $10,694
733 Added 7.32%
10,746 $113,000
Q3 2022

Nov 14, 2022

BUY
$13.1 - $20.34 $2,816 - $4,373
215 Added 2.19%
10,013 $181,000
Q2 2022

Aug 11, 2022

BUY
$12.37 - $21.86 $88,692 - $156,736
7,170 Added 272.83%
9,798 $139,000
Q1 2022

May 11, 2022

SELL
$15.94 - $23.34 $63,233 - $92,589
-3,967 Reduced 60.15%
2,628 $58,000
Q4 2021

Feb 10, 2022

BUY
$14.76 - $24.89 $97,342 - $164,149
6,595 New
6,595 $112,000

Others Institutions Holding AURA

About Aura Biosciences, Inc.


  • Ticker AURA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,273,600
  • Market Cap $268M
  • Description
  • Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develop...
More about AURA
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.